Immuno-Biological Laboratories Co Ltd
TSE:4570

Watchlist Manager
Immuno-Biological Laboratories Co Ltd Logo
Immuno-Biological Laboratories Co Ltd
TSE:4570
Watchlist
Price: 1 676 JPY 12.03% Market Closed
Market Cap: ¥15.6B

Operating Margin

28%
Current
Improving
by 12.6%
vs 3-y average of 15.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
28%
=
Operating Income
¥283.5m
/
Revenue
¥1B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
28%
=
Operating Income
¥283.5m
/
Revenue
¥1B

Peer Comparison

Country Company Market Cap Operating
Margin
JP
Immuno-Biological Laboratories Co Ltd
TSE:4570
15.6B JPY
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
236.2B USD
Loading...
US
Danaher Corp
NYSE:DHR
166B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
83T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
38.3B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
41.2B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
276.7B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.7B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.4B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
19.9B EUR
Loading...

Market Distribution

Higher than 93% of companies in Japan
Percentile
93rd
Based on 6 730 companies
93rd percentile
28%
Low
-125 500% — 4.2%
Typical Range
4.2% — 10.6%
High
10.6% — 9 743.7%
Distribution Statistics
Japan
Min -125 500%
30th Percentile 4.2%
Median 7%
70th Percentile 10.6%
Max 9 743.7%

Immuno-Biological Laboratories Co Ltd
Glance View

Immuno-Biological Laboratories Co., Ltd. engages in the manufacture and sale of antibody-related reagents and pharmaceutical products. The company is headquartered in Fujioka-Shi, Gumma-Ken(Gunma-Ken) and currently employs 65 full-time employees. The company went IPO on 2007-03-02. The firm operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.

Intrinsic Value
457.22 JPY
Overvaluation 73%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
28%
=
Operating Income
¥283.5m
/
Revenue
¥1B
What is Immuno-Biological Laboratories Co Ltd's current Operating Margin?

The current Operating Margin for Immuno-Biological Laboratories Co Ltd is 28%, which is above its 3-year median of 15.4%.

How has Operating Margin changed over time?

Over the last 3 years, Immuno-Biological Laboratories Co Ltd’s Operating Margin has increased from -5.9% to 28%. During this period, it reached a low of -5.9% on Sep 30, 2022 and a high of 28% on Sep 30, 2025.

Back to Top